Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02061748 · ClinicalTrials.gov registry record
The Comparative Safety and Effectiveness of Warfarin and Dabigatran Prescribed in the Non-valvular Atrial Fibrillation Population With Humana Healthcare Coverage
A clinical trial, sponsored by Boehringer Ingelheim.
- Completed
- Registry status
- 38,499
- Enrollment target
NCT02061748 is a clinical trial that has completed, run by Boehringer Ingelheim. The registered enrollment target is 38,499 participants.
The verdict
NCT02061748 has completed, sponsored by Boehringer Ingelheim.
- COMPLETED
- Registry status
- 38,499 participants
- Enrollment target
Study Summary
This study is an opportunity for Boehringer Ingelheim to collaborate with Humana to conduct comparative safety and effectiveness studies of dabigatran and warfarin using real world data from Humana's health plan operations.
Interventions
- DRUG Observational
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 38,499 participants |
| Start Date | 2014-10-28 |
| Est. Completion | 2016-03-15 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02061748
The ClinicalTrials.gov registry entry for NCT02061748 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 38,499 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Boehringer Ingelheim, which has 515 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Observational is the first listed.
NCT02061748 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02061748 about?
NCT02061748 is a clinical study titled "The Comparative Safety and Effectiveness of Warfarin and Dabigatran Prescribed in the Non-valvular Atrial Fibrillation Population With Humana Healthcare Coverage". This study is an opportunity for Boehringer Ingelheim to collaborate with Humana to conduct comparative safety and effectiveness studies of dabigatran and warfarin using real world data from Humana's health plan operations.
What is the current status of trial NCT02061748?
This trial is currently completed. The enrollment target is 38,499 participants. The study started on 2014-10-28. Estimated completion is 2016-03-15.
What interventions are being tested in trial NCT02061748?
The interventions under investigation include: Observational (DRUG).
Who is sponsoring clinical trial NCT02061748?
This trial is sponsored by Boehringer Ingelheim, which has 515 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.